Decorin mimic promotes endothelial cell health in endothelial monolayers and endothelial–smooth muscle co‐cultures. (1st June 2015)

• Record Type: Journal Article
• Authors: Scott, Rebecca A.; Ramaswamy, Aneesh K.; Park, Kinam; Panitch, Alyssa
• Is Part Of: Journal of tissue engineering and regenerative medicine. Volume 11:Number 5(2017)
• Page Start: 1365
• Page End: 1376
• Publication Date: 2015-06-01
• Subjects: decorin -- endothelial cells -- vascular smooth muscle cells -- co‐culture -- proteoglycan -- dermatan sulphate; Tissue engineering -- Periodicals; Regeneration (Biology) -- Periodicals; 610.28
• DOI: 10.1002/term.2035
• Languages: English
• ISSNs: 1932-6254

Abstract

Abstract: Non‐specific cytotoxins, including paclitaxel and sirolimus analogues, currently utilized as anti‐restenotic therapeutics, affect not only smooth muscle cells (SMCs) but also neighbouring vascular endothelial cells (ECs). These drugs inhibit the formation of an intact endothelium following vessel injury, thus emphasizing the critical need for new candidate therapeutics. Utilizing our in vitro models, including EC monolayers and both hyperplastic and quiescent EC–SMC co‐cultures, we investigated the ability of DS–SILY20, a decorin mimic, to promote EC health. DS–SILY20 increased EC proliferation and migration by 1.5‐ and 2‐fold, respectively, which corresponded to increased phosphorylation of ERK‐1/2. Interestingly, IL‐6 secretion and the production of both E‐selectin and P‐selectin were reduced in the presence of 10 μm DS–SILY20, even in the presence of the potent pro‐inflammatory cytokine platelet‐derived growth factor (PDGF). In hyperplastic and quiescent EC–SMC co‐cultures, DS–SILY20 treatment reduced the secretion of IFN γ, IL‐1 β, IL‐6 and TNF α, corresponding to a 23% decrease in p38 phosphorylation. E‐selectin and P‐selectin expression was further reduced following DS–SILY20 treatment in both co‐culture models. These results indicate that DS–SILY20 promotes EC health and that this decorin mimic could serve as a potential therapeutic to promote vessel healing following percutaneous coronary intervention (PCI). Copyright © 2015 John Wiley & Sons, Ltd.